Concentra Telemed
Search documents
Concentra Announces Preliminary 2025 Financial Results, Provides 2026 Financial Guidance, and Announces Q4 2025 Earnings Call Date
Businesswire· 2026-01-28 21:24
ADDISON, Texas--(BUSINESS WIRE)--Concentra Group Holdings Parent, Inc. ("Concentra,†the "Company,†"we,†"us,†or "our†) (NYSE: CON), the nation's largest provider of occupational health services by number of locations, today released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, exceeding its previously issued guidance for full year 2025. In addition, the Company is releasing its preliminary 2026 business outlook, and publishing a detailed Investor B ...
Concentra Acquires Reliant Immediate Care from MBI Industrial Medicine
Businesswire· 2026-01-19 13:00
Reliant Huntington Park at 5900 Pacific Boulevard, Huntington Park, California 90255, will close and merge with Concentra Vernon Soto at 3851 Soto Street, Vernon, California 90058. ADDISON, Texas--(BUSINESS WIRE)--Concentra®, the nation's leader in occupational medicine, today announced the acquisition of the assets of Reliant Immediate Care in California. Reliant Immediate Care was an MBI Industrial Medicine company. Reliant LAX Airport at 5901 West Century Boulevard, Los Angeles, California 90045, is now ...
The Upside Story Behind Concentra Group Holdings Parent, Inc. (CON)
Yahoo Finance· 2025-12-10 15:32
Group 1 - Concentra Group Holdings Parent, Inc. (NYSE:CON) is considered a cheap healthcare stock with a "Buy" rating from all seven analysts, indicating a median price target of $29, which suggests an upside potential of 48.95% from the current price [1] - Following the announcement of its third-quarter results, analysts reaffirmed their bullish outlook, with Mizuho Securities maintaining a Buy rating and a price target of $28, while Bank of America Securities also maintained a Buy rating [2] - In the third quarter, Concentra reported a 17% increase in revenue, an 8.9% increase in net income, and a 17.1% increase in adjusted EBITDA, driven by growth in patient volumes and revenue per visit [3]